Role of bile salt in regulating Mcl-1 phosphorylation and chemoresistance in hepatocellular carcinoma cells

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Liao, Mingmei ^a   Zhao, Jinfeng ^a   Wang, Ton ^b   Duan, Jinghua ^a   Zhang, Yangde ^a   Deng, Xingming ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; APURINIC ACID; CISPLATIN; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; GLYCOCHENODEOXYCHOLIC ACID; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN MCL 1; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BCL 2 LIKE PROTEIN 11; BCL-2-LIKE PROTEIN 11; CARCINOGEN; HUWE1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; ONCOPROTEIN; PROTEIN BCL 2; UBIQUITIN PROTEIN LIGASE;

APYRIMIDINIC SITE; ARTICLE; CELL SURVIVAL; CONCENTRATION RESPONSE; DNA DAMAGE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; CELL STRAIN HEPG2; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; LIVER TUMOR; METABOLISM; PHOSPHORYLATION; PROTEIN BINDING; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; CARCINOGENS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOCHENODEOXYCHOLIC ACID; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; UBIQUITIN-PROTEIN LIGASES;

EID: 79954620635     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-44     Document Type: Article

References (42)

1. Sieghart W, Losert D, Strommer S, Cejka D, Schmid K, Rasoul-Rockenschaub S, Bodingbauer M, Crevenna R, Monia B, Peck-Radosavljevic M, Wacheck V. Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy. J Hepatol 2006, 44:151-157. 10.1016/j.jhep.2005.09.010, 16289418.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917. 10.1016/S0140-6736(03)14964-1, 14667750.
3. Luo D, Cheng S, Xie H, Xie Y. Effects of Bcl2 and Bcl-XL protein levels on chemoresistance of hepatoblastoma HepG2 cell line. Biochem Cell Biol 2000, 78:119-126.
4. Kelekar A, Thompson CB. Bcl2-family proteins: the role of the BH3 domain in apoptosis. Trends in Cell Biology 1998, 8:324-330. 10.1016/S0962-8924(98)01321-X, 9704409.
5. De Biasio A, Vrana J, Zhou P, Qian L, Bieszczad C, Braley K, Domina A, Weintraub S, Neveu J, Lane W, Craig R. N-terminal Truncation of Antiapoptotic MCL1, but Not G2/M-induced Phosphorylation, Is Associated with Stabilization and Abundant Expression in Tumor Cells. J Biol Chem 2007, 282:23919-23936. 10.1074/jbc.M700938200, 17561513.
6. Chen L, Willis S, Wei A, Smith B, Fletcher J, Hinds M, Colman P, Day C, Adams J, Huang D. Differential targeting of prosurvival Bcl2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005, 17:393-403. 10.1016/j.molcel.2004.12.030, 15694340.
7. Kuwana T, Bouchier-Hayes L, Chipuk J, Bonzon C, Sullivan B, Green D, Newmeyer D. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005, 17:525-535.
8. Pagliari L, Kuwana T, Bonzon C, Newmeyer D, Tu S, Beere H, Green D. The multidomain proapoptotic molecules Bax and Bak are directly activated by heat. Proc Natl Acad Sci USA 2005, 102:17975-17980. 10.1073/pnas.0506712102, 1312392, 16330765.
9. Letai A. Bcl2: found bound and drugged!. TRENDS in Molecular Medicine 2005, 11:442-444. 10.1016/j.molmed.2005.08.007, 16150641.
10. Hikita H, Takehara T, Shimizu S, Kodama T, Li W, Miyagi T, Hosui A, Ishida H, Ohkawa K, Kanto T, Hiramatsu N, Yin XM, Hennighausen L, Tatsumi T, Hayashi N. Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. Hepatology. 2009, 50:1217-1226.
11. Vick B, Weber A, Urbanik T, Maass T, Teufel A, Krammer PH, Opferman JT, Schuchmann M, Galle PR, Schulze-Bergkamen H. Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes. Hepatology 2009, 49:627-636. 10.1002/hep.22664, 2753874, 19127517.
12. Domina AM, Smith JH, Craig RW. Myeloid cell leukemia 1 is phosphorylated through two distinct pathways, one associated with extracellular signal-regulated kinase activation and the other with G2/M accumulation or protein phosphatase 1/2A inhibition. J Biol Chem 2000, 275:21688-21694. 10.1074/jbc.M000915200, 10777489.
13. Isomoto H, Kobayashi S, Werneburg N, Bronk S, Guicciardi ME, Frank D, Gores GJ. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005, 42:1329-1338. 10.1002/hep.20966, 16317687.
14. Schuber K, Duronio V. Distinct roles for extracellular-signal-regulated protein kinase (ERK) mitogen-activated protein kinases and phosphatidylinositol 3-kinase in regulation of Mcl-1 synthesis. Biochem J Leukoc Biol 2001, 356:473-480.
15. Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci 2009, 66:1326-1336. 10.1007/s00018-008-8637-6, 19099185.
16. Bingle CD, Craig RW, Swales BM, Singleton V, Zhou P, Whyte MK. Exon skipping in Mcl-1 results in a bcl-2 homology domain 3 only gene product that promotes cell death. J Biol Chem 2000, 275:22136-22146. 10.1074/jbc.M909572199, 10766760.
17. Kobayashi S, Lee S, Meng X, Mott J, Bronk S, Werneburg N, Craig R, Kaufmann S, Gores G. Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem 2007, 282:18407-18417. 10.1074/jbc.M610010200, 17463001.
18. Domina A, Vrana J, Gregory M, Hann S, Craig R. Mcl-1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 2004, 23:5301-5315. 10.1038/sj.onc.1207692, 15241487.
19. Maurer U, Charvet C, Wagman A, Dejardin E, Green D. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of Mcl-1. Mol Cell 2006, 21:749-760. 10.1016/j.molcel.2006.02.009, 16543145.
20. Zhao J, Xin M, Wang T, Zhang Y, Deng X. Nicotine enhances the antiapoptotic function of Mcl-1 through phosphorylation. Mol Cancer Res 2009, 7:1954-1961. 10.1158/1541-7786.MCR-09-0304, 2796280, 19903766.
21. Stieger B. Recent insights into the function and regulation of the bile salt export pump (ABCB11). Current Opinion in Lipidology 2009, 20:176-181. 10.1097/MOL.0b013e32832b677c, 19684528.
22. Prieto AI, Ramos-Morales F, Casadesús J. Repair of DNA damage induced by bile salts in Salmonella enterica. Genetics 2006, 174:575-584. 10.1534/genetics.106.060889, 1602091, 16888329.
23. Komichi D, Tazuma S, Nishioka T, Hyogo H, Chayama K. Glycochenodeoxycholate plays a carcinogenic role in immortalized mouse cholangiocytes via oxidative DNA damage. Free Radic Biol Med 2005, 39:1418-1427. 10.1016/j.freeradbiomed.2005.07.005, 16274877.
24. Jaiswal K, Lopez-Guzman C, Souza R, Spechler S, Sarosi G. Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non-neoplastic Barrett's cell line. Am J Physiol Gastrointest Liver Physiol 2006, 290:G335-G342. 10.1152/ajpgi.00167.2005, 16239404.
25. Jaiswal K, Tello V, Lopez-Guzman C, Nwariaku F, Anthony T, Sarosi G. Bile salt exposure causes phosphatidyl-inositol-3-kinase-mediated proliferation in a Barrett's adenocarcinoma cell line. Surgery 2004, 136:160-168. 10.1016/j.surg.2004.04.008, 15300175.
26. Yoon JH, Werneburg NW, Higuchi H, Canbay AE, Kaufmann SH, Akgul C, Edwards SW, Gores GJ. Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res 2002, 62:6500-6505.
27. Arnold H, Sears R. Protein phosphatase 2A regulatory subunit B56α associates with c-Myc and negatively regulates c-Myc accumulation. Mol Cell Biol 2008, 26:2832-2844.
28. Deng X, Gao F, Flagg T, May WS. Mono- and multi-site phosphorylation enhances Bcl2's anti-apoptotic function and inhibition of cell cycle entry functions. Proc Natl Acad Sci USA 2004, 101:153-158. 314154, 14660795.
29. Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005, 121:1085-1095. 10.1016/j.cell.2005.06.009, 15989957.
30. O'Reilly EM, Stuart KE, Sanz-Altamira PM, Schwartz GK, Steger CM, Raeburn L, Kemeny NE, Kelsen DP, Saltz LB. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 2001, 91:101-105. 10.1002/1097-0142(20010101)91:1<101::AID-CNCR13>3.0.CO;2-K, 11148565.
31. Boige V, Taïeb J, Hebbar M, Malka D, Debaere T, Hannoun L, Magherini E, Mignard D, Poynard T, Ducreux M. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer 2006, 42:456-459. 10.1016/j.ejca.2005.09.034, 16427779.
32. Toke O, Monsey JD, DeKoster GT, Tochtrop GP, Tang C, Cistola DP. Determinants of cooperativity and site selectivity in human ileal bile acid binding protein. Biochemistry 2006, 45:727-737. 10.1021/bi051781p, 16411748.
33. Bernstein H, Bernstein C, Payne CM, Dvorak K. Bile acids as endogenous etiologic agents in gastrointestinal cancer. World J Gastroenterol 2009, 15:3329-3340. 10.3748/wjg.15.3329, 2712893, 19610133.
34. Zhou P, Levy NB, Xie H, Qian L, Lee CY, Gascoyne RD, Craig RW. MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood 2001, 97:3902-3909. 10.1182/blood.V97.12.3902, 11389033.
35. Low HW. Targeting Ras-RAF-ERK and its interactive pathways as novel therapy for malignant gliomas. Curr Cancer Drug Targets 2010, 10:840-848. 10.2174/156800910793357970, 20718706.
36. Challen C, Guo K, Collier JD, Cavanagh D, Bassendine MF. Infrequent point mutations in codons 12 and 16 of ras oncogenes in human hepatocellular carcinomas. J Hepatol 1992, 14:342-346. 10.1016/0168-8278(92)90181-N, 1323601.
37. Tada M, Omata M, Ohto M. Analysis of ras gene mutations in human hepatic malignant tumor by polymerase chain reaction and direct sequencing. Cancer Res 1990, 50:1121-1124.
38. Tada M, Omata M, Ohto M. Detection of ras gene mutations of primary hepatic malignant tumors by polymerase chain reaction and direct sequencing. Nippon Shokakibyo Gakkai Zasshi 1990, 87:811-815.
39. Stork P, Loda M, Bosari S, Wiley B, Poppenhusen K, Wolfe H. Detection of K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction. Oncogene 1991, 6:857-862.
40. Liu H, Peng H, Cheng Y, Yuan H, Yang Y. Stabilization and enhancement of the antiapoptotic activity of Mcl-1 by TCTP. Mol Cell Biol 2005, 25:3117-3126. 10.1128/MCB.25.8.3117-3126.2005, 1069602, 15798198.
41. Jin Z, May WS, Gao F, Flagg T, Deng X. Bcl2 suppresses DNA repair by enhancing c-Myc transcriptional Activity. J Biol Chem 2006, 281:14446-14456. 10.1074/jbc.M511914200, 16554306.
42. Zhao J, Gao F, Zhang Y, Wei K, Liu Y, Deng X. Bcl2 inhibits abasic site repair by down-regulating APE1 endonuclease activity. J Biol Chem 2008, 283:9925-9932. 10.1074/jbc.M708345200, 2442307, 18263880.